Android app on Google Play

Gilead's (GILD) HCV Treatment Sovaldi Shows Strong Early Adoption (VRTX) (MRK)

December 27, 2013 12:05 PM EST Send to a Friend
Get Alerts GILD Hot Sheet
Price: $74.08 +0.30%

Rating Summary:
    21 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 26 | Down: 10 | New: 8
Trade GILD Now!
Join SI Premium – FREE
Gilead Sciences (Nasdaq: GILD) is lower amid strong data backing its hepatits C drug, Sovaldi.

Bloomberg cites Symphony Health data in reporting that prescriptions for Sovaldi rose 284 percent to 932 during its second week on the U.S. market. While data is still early, Sovaldi appears to be comparing favorably to Vertex's (Nasdaq: VRTX) Incivek, which didn't achieve a similar level unit it was on the market about a month. Merck's (NYSE: MRK) Victrelis was said to have exceeded the 900 level for only one week since its debut.

Shares of Gilead are down 0.7 percent Friday.




You May Also Be Interested In


Related Categories

Analyst Comments, FDA

Add Your Comment